Key Points:
- Combining Immorta Bio’s vaccine and stem cell therapy doubled lifespan in a mouse model of aging, a substantial feat.
- The combination also reduced markers of the SASP—inflammatory molecules excreted by senescent cells.
- The combination significantly improved physical performance, most notably enhancing climbing ability.
As reported in a YouTube segment, the biotech company, Immorta Bio Inc., released data showing that its vaccine, SenoVax, combined with its stem cell therapy, StemCellRevivify, doubled lifespan in a mouse model of aging. The mouse model displays accelerated aging from a high burden of senescent cells. Senescent cells are cells that stop dividing but do not die, and also accumulate with age, a hallmark of aging.
In the same mouse model, the vaccine also reduced markers of the SASP, which encompasses inflammatory molecules secreted by senescent cells. Moreover, the vaccine improved markers of liver function and significantly improved physical function. These data, which still require going through a peer review process, suggest that combining vaccines like SenoVax that target senescent cells with stem cell therapy may help extend life without debilitating diseases.
“These data support a new paradigm in longevity medicine,” said Dr. Thomas Ichim, Immorta Bio’s President and Chief Scientific Officer, in a press release.
Background on Senescent Cells
As people get older, numerous cells stop dividing and performing their typical functions, and the immune system loses its capacity to clear them out with advanced age. These are senescent cells. Some researchers say that up to 10% of cells in certain tissues can have at least some markers of senescence with advanced age.
The occurrence of senescence in cells is actually a safety feature, preventing damaged cells from turning into cancer. As these cells accumulate with age, though, a portion of them starts excreting SASP inflammatory molecules. The SASP does damage, accelerating senescence in surrounding cells, degrades tissues, suppresses stem cells, and can even promote cancer growth.
When someone is young, their immune system clears senescent cells out pretty efficiently; however, with age, more senescent cells accumulate, and the immune system gets worse at clearing them. The result is that by age 60, 70, or 80, people carry around precipitously greater burdens of senescent cells that may drive nearly every disease related to aging, such as arthritis, Alzheimer’s, kidney failure, heart disease, and cancer.
The question becomes how to eliminate these senescent cells. For this purpose, researchers have developed agents, known as senolytics, that get rid of senescent cells. One of the most well-known combinations of senolytics, dasatinib and quercetin, has actually been shown to improve physiological function in aged mice and extend lifespan. However, these agents have been shown to kill only some types of senescent cells, and they have off-target effects, potentially killing functional, non-senescent cells.
As such, evidence supports the concept of using senolytics to kill senescent cells, but senolytics currently lack the precision necessary to effectively eliminate different kinds of senescent cells across organ systems. To refine the therapeutic tools scientists use against senescent cells, Immorta Bio developed SenoVax.
“We found something that we believe is first-in-class—a completely new way of extending lifespan, which is using the immune system to kill senescent cells,” says Dr. Ichim. “And when you kill the old cells, the younger ones take over.”
SenoVax Targets Senescent Cells
SenoVax is a personalized immunotherapy. Its mechanism of action entails extracting a patient’s immune cells, known as dendritic cells, outside of the body and pulsing them with exposures to senescent cells in a laboratory. The dendritic cells learn the surface markers of the senescent cells, thereby creating a sort of immune memory of senescent cells. When the dendritic cells are injected back into the patient, the dendritic cells teach other immune cells, called T cells, to attack senescent cells. Thus, all cells with the cellular markers of the senescent cells that were presented to the dendritic cells in a laboratory get targeted.
In addition to targeting senescent cells, Immorta Bio created another platform called StemCellRevivify to help rejuvenate aged tissues following senescent cell clearance. This system uses stem cells derived from each patient. These personalized stem cells can help repair bone, cartilage, fat, and other types of connective tissue cells. These stem cells also release powerful anti-inflammatory and regenerative signals that help damaged tissues heal.
The complication with typical stem cell therapies, according to Dr. Ichim, is the cellular environment that surrounds them. If you inject stem cells into tissues that have an abundance of senescent cells and inflammatory SASP factors, those stem cells do not survive long enough to promote tissue healing.
“Senescent cells and their inflammatory secretions actively inhibit tissue regeneration,” says Dr. Ichim. “By first removing this barrier with SenoVax, we enable personalized regenerative stem cells to restore function in ways not achievable with either approach alone.”
The idea is to remove the barrier to healing, senescent cells, and then rebuild tissues with stem cells. Moreover, Immorta Bio did not stop with one type of tissue, but has expanded the StemCellRevivify platform for regeneration of the heart, brain, and liver.
Combining SenoVax and StemCellRevivify Doubles Mouse Lifespan
In January 2026, at the J.P. Morgan Biotech Showcase, one of the largest biotech conferences in the world, Immorta Bio presented its data pertaining to combining SenoVax with StemCellRevivify. The data came from testing their combination therapy in a well-established mouse model of aging, the doxurubicin-induced systemic senescent model. In this model, a chemotherapy drug, doxorubicin, is used to induce widespread, persistent DNA damage, causing normal cells to enter a permanent state of senescence. Accordingly, in this model, the chemotherapeutic agent floods the mice’s bodies with senescent cells.
Immorta Bio researchers treated these mice with both SenoVax and StemCellRevivify alone, which significantly extended lifespan. Intriguingly, combining the therapies worked substantially better than either therapy alone, doubling lifespan. These data show that Immorta Bio’s combination of therapies dramatically extends lifespan in this mouse model of aging.
To put this lifespan extension achievement into perspective, a handful of therapies, such as calorie restriction, can extend mouse lifespan by 20% to 30%, albeit in naturally aged mice. The doubling of lifespan in this mouse model could put Immorta Bio’s combination of therapies into a new category of lifespan-extending treatments; however, it appears that no other lifespan studies using this accelerated aging mouse model have been conducted to date. Thus, no data exists with which to compare Immorta Bio’s results. For this reason, it is difficult to assess the degree of significance of ImmortaBio’s combination therapy on longevity. All the same, people at Immorta Bio seem optimistic about the dual therapy’s potential to extend the number of years without debilitating diseases.
“Our senolytic and immortal stem cell technologies open new frontiers—not just for aging, but conditions once thought irreversible,” says Dr. Boris Reznik, Chairman and CEO of Immorta Bio.
Moreover, aside from doubling lifespan in this mouse model, the mice also showed improved physiological function compared to either therapy alone. For example, the combination significantly lowered SASP factor markers, boosted rejuvenation factors (molecules associated with tissue repair), improved markers of liver function, and enhanced physical performance (for example, the mice showed improved climbing strength).
Testing Immorta Bio’s SenoVax in Human Patients with Cancer
Immorta Bio’s combination of therapies could help alleviate multiple age-related diseases, notably cancer. Along these lines, as it turns out, cancer cells are surrounded by senescent cells and require senescent cells to grow. For example, tumors create an accelerated aging environment in their surroundings, triggering cells in their proximity to enter senescence. Nearby senescent cells then pump out growth factors that feed cancer. In this way, tumors build their own supporting senescent cells in their surroundings that help them grow. Theoretically, with SenoVax treatment, the tumors’ senescent cell support system collapses.
“We use it for cancer. Why cancer?” posed Dr. Ichim. “Because cancer surrounds itself with senescent cells. Many studies have shown that for cancer to grow, it actually needs to make the cells around it accelerate in aging, and these old cells provide growth factors that allow the cancer to continue growing.”
Relatedly, Immorta Bio has published data showing that SenoVax reduces tumors in mouse models of lung, breast, pancreatic, and brain cancers. The company has also shown that combining SenoVax with other cancer immunotherapies produces synergistic effects in reducing tumors.
Due to SenoVax’s anti-cancer effects in mice, Immorta Bio has submitted an investigational new drug (IND) application to the FDA. If Immorta Bio’s submission is approved as an IND, Immorta Bio can start testing SenoVax in humans to determine its safety and efficacy. Thus, if approved, patients with lung cancer may participate in clinical trials to assess the safety and efficacy of SenoVax.
Confirming the Therapeutic Combination’s Efficacy in Naturally Aged Mice
Also of importance, Immorta Bio researchers need to test the lifespan effects of the combination of SenoVax and StemCellRevivify in naturally aged mice. Naturally aged mice lifespan studies may serve as a better indicator of how well the combination therapy influences longevity, as opposed to the chemotherapy drug-induced accelerated aging model that the company used.
Once tested in naturally aged mice, the next step would be to evaluate the therapeutic combination’s effects on aspects of aging in humans. If the pro-longevity effects translate to humans, Immorta Bio’s SenoVax and StemCellRevivify combination therapy may serve as a new way to extend disease-free life in the next 10 to 15 years.
Comments